Kymera Therapeutics
NASDAQ: KYMRIncorporated in Delaware · 9 known investors
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.
Investors · 9
Atlas VentureCambridge · $500K – $1M
Avoro Capital AdvisorsNew York
Bain Capital Life SciencesBoston
Bessemer Venture PartnersRedwood City · $5M – $100M
Nextech InvestZurich · $648K – $3.2M
Pfizer Venture Investments$5M – $20M
Sanofi VenturesCambridge · $5M
Solasta VenturesBoston
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4M